Cardiac mesenchymal cells from failing hearts retained the potential to limit ventricular remodeling when administered late after myocardial infarction in a chronic preclinical model.
Do cardiac mesenchymal cells from failing hearts limit ventricular dilation when administered late after infarction in a chronic model of myocardial infarction?
Cardiac mesenchymal cells derived from failing hearts maintain their ability to limit ventricular remodeling after myocardial infarction, suggesting donor heart failure may not preclude their use in cell therapy.
Most preclinical studies have used only cells from healthy, nonfailing hearts. Whether donor condition (i.e., heart failure) impacts cells used for cell therapy is not known. We directly tested whether donor condition impacted the reparative effects of cardiac mesenchymal cells in a chronic model of myocardial infarction. Although cells from failing hearts differed in multiple aspects, they retained the potential to limit ventricular remodeling.
Audam et al. (Fri,) conducted a other in Myocardial infarction. Cardiac mesenchymal cells from failing hearts vs. Cardiac mesenchymal cells from nonfailing hearts was evaluated on Ventricular remodeling. Cardiac mesenchymal cells from failing hearts retained the potential to limit ventricular remodeling when administered late after myocardial infarction in a chronic preclinical model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: